An observational study in Invasive Candidiases, sponsored by University of Cologne. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-12-12.
Sponsored by University of Cologne · Observational
The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive Candida infections and to function as a platform for future studies and in case of outbreaks.
The specific objectives are:
To describe the global incidence of invasive Candida infection To monitor trends globally and locally over time To define patient risk groups To assess antifungal resistance among Candida spp. causing invasive diseases worldwide To assess attributable mortality of invasive Candida infection To assess incremental costs associated with invasive Candida infection
To describe the clinical pattern of disease To document diagnostic procedures performed for confirmation of diagnosis To describe first-line and salvage treatment regimens applied, guideline adherence, their efficacy and impact on patient survival To inform consensus guidelines To develop clinical screening and diagnostic procedures
Set up of a collection of isolates with molecular characterization and evaluation of resistance genes
Invasive infections caused by Candida species
Matching procedure for controls:
In part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital).
Controls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization
Exclusion Criteria:
Web-based registry of invasive infections by Candida species
Incidence
To describe the global incidence of invasive Candida infection
Time frame: up to 100 weeks
Mortality
To describe the global mortality of invasive Candida infection
Time frame: up to 100 weeks
Molecular characteristics of Candida auris
To describe the molecular characteristics of Candida auris
Time frame: At 90 Days from diagnosis
Susceptibility testing
To describe the susceptibility of Candida auris
Time frame: At 90 Days from diagnosis
Resistance development
To describe the resistance development of Candida auris
Time frame: up to 100 weeks
Treatment efficacy of invasive candida infections
Number of participants with treatment failure
Time frame: At 90 Days from diagnosis
Treatment efficacy of invasive candida infections
Number of participants with stable disease
Time frame: At 90 Days from diagnosis
Treatment efficacy of invasive candida infections
Number of participants with partial response
Time frame: At 90 Days from diagnosis
Treatment efficacy of invasive candida infections
Number of participants with complete response
Time frame: At 90 Days from diagnosis
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cologne